CN1985881A - Preparing process and application of compound red sage and chuanxiong rhizome oral preparation - Google Patents
Preparing process and application of compound red sage and chuanxiong rhizome oral preparation Download PDFInfo
- Publication number
- CN1985881A CN1985881A CN 200510132502 CN200510132502A CN1985881A CN 1985881 A CN1985881 A CN 1985881A CN 200510132502 CN200510132502 CN 200510132502 CN 200510132502 A CN200510132502 A CN 200510132502A CN 1985881 A CN1985881 A CN 1985881A
- Authority
- CN
- China
- Prior art keywords
- extract
- weight portion
- salviae miltiorrhizae
- borneolum syntheticum
- radix salviae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention discloses preparation process and application of compound red sage-Chuanxiong rhizome oral preparation. The preparation process includes preparing red sage extract and notoginseng extract with red sage extract and notoginseng and through separated water extracting, concentrating, centrifuging, eluting in adsorption resin column with water and alcohol and decompression concentrating; preparing Chuanxiong rhizome extract with Chuanxiong rhizome and through reflux extracting, and eluting in macroporous adsorption resin with water and alcohol; clathrating borneol with beta-CD; mixing the clathrate, extracts and supplementary material; and further treating the mixture to obtain the target preparation. The compound red sage-Chuanxiong rhizome oral preparation has obvious treating effect on coronary heart disease, angina and other cardiac vascular diseases.
Description
Technical field
The invention belongs to technical field of traditional Chinese medicine pharmacy, be specifically related to a kind of preparation method and application thereof of compound red sage and chuanxiong rhizome oral preparation.
Background technology
Coronary heart disease is the highest disease of case fatality rate in the cardiovascular disease, is one of human three big causes of the death.In recent years, along with the raising of social life level and the aging of population, its sickness rate is the trend that rises year by year, and the medicine of exploitation treatment cardiovascular and cerebrovascular disease gradually becomes the focus of research.Increasing clinical report shows that Chinese medicine is having a good application prospect aspect treatment coronary heart disease, the angina pectoris, and particularly the few side effects of Chinese medicine is subjected to liking of people day by day.Its cause of disease of coronary heart disease be since some can not to infilter the blood-lipoids material of arterial wall such as cholesterol, glycerol three cruel etc., be deposited on and form " atheromatous plaque " back on the endarterium because of calmness calcareous in the liquid, make original whippy tremulous pulse hardening, along with the atheromatous plaque scope on the endarterium strengthens, cause lumen of vessels to narrow down even block, cause myocardial ischemia, anoxia or necrosis.Ischemia apoplexy (cerebral infarction) all is important opportunitys of its prevention and treatment at acute attack stage and in apoplexy early stage and convalescent period.Chinese medicine plays an important role in above-mentioned prevention and treatment of diseases, especially the folk prescription or the compound preparation that with the Radix Salviae Miltiorrhizae are primary raw material all have definite curative effect, as preparations such as FUFANG DANSHEN PIAN, FUFANG DANSHEN ZHUSHEYE, FUFANG DANSHEN DIWAN, red-rooted-salvia-root chuanxiong-rhizome azine injecta, compound red sage and chuanxiong rhizome sheets.Radix Salviae Miltiorrhizae, Radix Notoginseng, Rhizoma Chuanxiong are all being brought into play main therapeutical effect aspect the diseases such as treatment coronary heart disease, angina pectoris in these preparations.
Radix Salviae Miltiorrhizae is the dry root and rhizome of Labiatae salvia SalviamiltiorrhizaBge.Red sage root water soluble ingredient is mainly Radix Salviae Miltiorrhizae acids such as danshensu, protocatechualdehyde and protocatechuic acid, is the main composition that resists myocardial ischemia.Radix Notoginseng is the dry root of araliaceae ginseng plant Panaxnotoginseng (Burk.) F.H.Chen, and main component is a saponin component, Radix Notoginseng bitter but sweet flavor and temperature has good hemostasis, analgesic effect, and the effect of blood circulation promoting and blood stasis dispelling is arranged.Rhizoma Chuanxiong is Chinese medicine samphire (Ligus-ticum Chuanxiong) rhizome, and its effective ingredient ligustrazine has the pharmacological action of blood circulation promoting and blood stasis dispelling, anti-platelet aggregation, expansion small artery etc.The hot perfume (or spice) of Borneolum Syntheticum is walked to scurry, and is cold, has the effect of the refreshment of having one's ideas straightened out, clearing away heat to alleviate pain, is applicable to the obstructed diseases such as obstruction of qi in the chest and cardialgia that cause of heart arteries and veins.
Summary of the invention
The present invention is developed into a kind of compound red sage and chuanxiong rhizome oral preparation according to main active and Pharmacological action study thereof to Radix Salviae Miltiorrhizae, Radix Notoginseng, Rhizoma Chuanxiong and Borneolum Syntheticum, and preparation of the present invention merges Radix Salviae Miltiorrhizae, pseudo-ginseng powder, with the water reflux, extract,, extracting solution concentrates, macroporous adsorptive resins on the supernatant of centrifugal back, with water elution to sugar-free, continue and use ethanol elution, reclaim ethanol elution, concentrating under reduced pressure, drying, get Radix Salviae Miltiorrhizae, Radix Notoginseng extract, be mainly Radix Salviae Miltiorrhizae acids and Radix Notoginseng total arasaponins.Szechwan Lovage Rhizome acidic alcohol reflux, extract,, the leaching medicinal liquid concentrates, adjust pH, with water saturated ethyl acetate extraction, extract is again with the saturated water washing of ethyl acetate, reclaim ethyl acetate, insoluble matter is with the hot water dissolving, last macroporous adsorptive resins, elder generation's water is eluted to colourless, the reuse ethanol elution merges ethanol elution, concentrating under reduced pressure, drying gets Rhizoma Chuanxiong extract.The Borneolum Syntheticum dissolve with ethanol, beta-cyclodextrin inclusion compound.With said extracted thing and cyclodextrin inclusion mix homogeneously, add required adjuvant, make target formulation.The pharmacological results shows that compound red sage and chuanxiong rhizome oral preparation of the present invention has the obvious treatment effect to the disease of cardiovascular aspects such as treatment coronary heart disease, angina pectoris.
The object of the invention is to provide a kind of compound red sage and chuanxiong rhizome oral preparation;
The object of the invention also is to provide a kind of preparation method of compound red sage and chuanxiong rhizome oral preparation;
The present invention is achieved through the following technical solutions:
One, preparation method
1. the prescription of crude drug is:
Radix Salviae Miltiorrhizae 150-300 weight portion, Radix Notoginseng 50-100 weight portion, Rhizoma Chuanxiong 50-100 weight portion, Borneolum Syntheticum 0.5-3 weight portion;
2. the extraction of effective ingredient:
(1) gets Radix Salviae Miltiorrhizae, pseudo-ginseng pulverizing, use distilled water reflux, extract, 2-4 time, each 1-3h, filter, merge the water extract, being evaporated to relative density is 1.0～1.5, leave standstill centrifugalize, macroporous adsorptive resins on the supernatant, earlier be eluted to sugar-free, continue, reclaim ethanol elution with the ethanol elution of 40-80% with distilled water, concentrating under reduced pressure, drying gets Radix Salviae Miltiorrhizae, Radix Notoginseng total extract, and being mainly with the danshensu is the Radix Salviae Miltiorrhizae acids and the Radix Notoginseng total arasaponins of main component.
(2) get the Rhizoma Chuanxiong pulverizing medicinal materials, with HCl ethanol (concentration of alcohol the is 45-75%) reflux, extract, of 0.5-3%, the leaching medicinal liquid is concentrated into about 1-2g medical material/mL, uses Na
2CO
3Adjust pH to 7～10, with water saturated ethyl acetate extraction, extract reclaims ethyl acetate again with the saturated water washing of ethyl acetate, insoluble matter is with the hot water dissolving, last macroporous adsorptive resins, first water is eluted to colourless, the ethanol elution of reuse 40-70%, merge ethanol elution, concentrating under reduced pressure (＜60 ℃), drying, obtaining with the ligustrazine is the Rhizoma Chuanxiong extract of main active.
(3) Borneolum Syntheticum becomes near saturated solution standby with anhydrous alcohol solution; Other gets β-CD adding distil water that 3-15 doubly measures and makes saturated solution, and Borneolum Syntheticum ethanol liquid slowly is added drop-wise in β-CD saturated solution, does not stop to stir.After adding, 50 ± 5 ℃ are continued to stir 2-4h again, and cold preservation is spent the night, and filters, and the precipitation cold drying gets the Borneolum Syntheticum beta-CD inclusion.
3. preparation prescription:
Tablet formulation consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 4-10 weight portion, and Rhizoma Chuanxiong extract 1-3 weight portion, Borneolum Syntheticum beta-CD inclusion 0.01-0.6 weight portion, pharmaceutic adjuvant is the 2.5-40 weight portion;
The granule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 4-10 weight portion, Rhizoma Chuanxiong extract 1-3 weight portion, Borneolum Syntheticum beta-CD inclusion 0.01-0.6 weight portion, pharmaceutic adjuvant 5-110 weight portion;
The capsule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 4-10 weight portion, and Rhizoma Chuanxiong extract 1-3 weight portion, Borneolum Syntheticum beta-CD inclusion 0.01-0.6 weight portion, pharmaceutic adjuvant is the 5-40 weight portion;
The soft capsule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 4-10 weight portion, and Rhizoma Chuanxiong extract 1-3 weight portion, Borneolum Syntheticum beta-CD inclusion 0.01-0.6 weight portion, pharmaceutic adjuvant is the 5-55 weight portion;
The drop pill prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 4-10 weight portion, and Rhizoma Chuanxiong extract 1-3 weight portion, Borneolum Syntheticum beta-CD inclusion 0.01-0.6 weight portion, pharmaceutic adjuvant is the 10-82 weight portion;
The oral liquid formulations prescription is formed: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 4-10 weight portion, and Rhizoma Chuanxiong extract 1-3 weight portion, Borneolum Syntheticum beta-CD inclusion 0.01-0.6 weight portion, pharmaceutic adjuvant is the 0.5-2 weight portion;
4. formulation preparation:
Get Radix Salviae Miltiorrhizae, Radix Notoginseng total extract, Rhizoma Chuanxiong extract and Borneolum Syntheticum beta-CD inclusion, add acceptable pharmaceutic adjuvant on the pharmaceutics, be prepared into tablet, granule, capsule, soft capsule, drop pill, oral liquid formulations with conventional pharmaceutical technology;
Two, detection method
1. Radix Salviae Miltiorrhizae total phenolic acids check and analysis
According to high effective liquid chromatography for measuring.
Chromatographic condition and system suitability test: with octadecylsilane chemically bonded silica is filler; With methanol: glacial acetic acid: water (25: 1: 224) is mobile phase; The detection wavelength is 280nm.Number of theoretical plate is pressed the protocatechualdehyde peak and is calculated, and should be not less than 1500.
The preparation of reference substance solution: precision takes by weighing the protocatechualdehyde reference substance 10mg that is dried to constant weight at 105 ℃, puts in the 100ml measuring bottle, adds mobile phase to scale, shakes up.Precision is measured 2ml, puts in the 10ml measuring bottle, adds mobile phase to scale, shakes up, and promptly gets (containing protocatechualdehyde 0.02mg among every 1ml).
Algoscopy: precision is measured this product 500mg, puts in the 100ml measuring bottle, adds mobile phase to scale, shakes up.Precision is measured 10 μ l and is injected chromatograph of liquid, the record chromatogram; Other gets reference substance solution, measures with method, presses external standard method with calculated by peak area, promptly.Measurement result sees Table 1:
2. ligustrazine check and analysis
The content of rp-hplc determination ligustrazine
Experimental apparatus: Hitachi655A pump, variable-wavelenght detector, ShiridoC-R4A chromatography system.
Experimental drug: the ligustrazine reference substance is available from Chinese biological goods calibrating institute, and methanol is chromatographically pure, and water is double distilled water, and other reagent is analytical pure.
Chromatographic condition and system suitability test: the ZorbaxC18 analytical column (4.6mm * 250mm); Mobile phase: methanol: water (1% acetic acid)=35: 65, flow velocity 0.8ml/min; Detect wavelength: 300nm.
The preparation of reference substance solution: precision takes by weighing the about 4mg of reference substance, puts in the 10ml measuring bottle, and the adding distil water dissolving also is diluted to scale, shakes up, as storing solution; Accurate respectively absorption 0.1,0.2,0.4,0.6,0.8,1.0ml put in the 10ml volumetric flask, and adding distil water is diluted to scale, shakes up, in contrast product solution.
The preparation of reference substance solution: oral formulations of the present invention is got 0.6g, and accurate the title, decide, and puts in the tool plug conical flask, the accurate methanol 50ml that adds, close plug claims to decide weight, remove plug, change condensing tube, reflux 1h, put coldly, close plug claims to decide weight again, supply the weight that subtracts mistake with methanol, shake up, filter, get subsequent filtrate, as need testing solution.
Algoscopy: accurate respectively reference substance solution and each 8 μ l of need testing solution of drawing, injecting chromatograph is measured content.The results are shown in Table 1:
Active constituent content relatively in table 1 compound red sage and chuanxiong rhizome oral preparation
| Group | Radix Salviae Miltiorrhizae total phenolic acids (in catechu aldehyde) (mgg-1) | Ligustrazine (μ gg-1) |
| Compound red sage and chuanxiong rhizome tablet compound red sage and chuanxiong rhizome granule compound red sage and chuanxiong rhizome capsule preparations compound red sage and chuanxiong rhizome soft capsule preparation compound red sage and chuanxiong rhizome dropping pill formulation compound red sage and chuanxiong rhizome oral liquid formulation | 0.276 0.281 0.293 0.297 0.301 0.289 | 1.402 1.426 1.458 1.483 1.596 1.501 |
Result: show that by above check and analysis experiment technology of the present invention has practical significance.
Three, pharmacology embodiment
1. the influence of anoxia in mice endurance is tested
Experimental technique: get 80 of healthy Kunming mouses, body weight 20～24g.Be divided into matched group at random, composite salvia dropping pill group, compound red sage and chuanxiong rhizome oral preparation group of the present invention.Every group 10, male and female half and half, sub-cage rearing.With the conversion of people's conventional therapy dosage is the dosage of mice.The conversion formula is: tested animal is tried out the body surface area ratio of the body surface area ratio/known animal of dosage=known animals administer amount * tested animal.Control group administered physiological saline, 1 time/d, continuous 7d.1h after the last administration, it is the 150ml port grinding bottle that mice is placed volume respectively, in put the 15g sodica calx, its time-to-live of airtight observation, the results are shown in Table 2.
The influence of table 2 pair mice normobaric hypoxia
| Group | Mus number (only) | Mean survival time (min) |
| Matched group | 10 | 12.6±1.2 |
| Composite salvia dropping pill group | 10 | 20.3±1.5 * |
| Compound red sage and chuanxiong rhizome tablet compound red sage and chuanxiong rhizome granule compound red sage and chuanxiong rhizome capsule preparations compound red sage and chuanxiong rhizome soft capsule preparation compound red sage and chuanxiong rhizome dropping pill formulation compound red sage and chuanxiong rhizome oral liquid formulation | 10 10 10 10 10 10 | 25.9±1.3 *# 26.8±1.7 *# 27.6±1.4 *# 28.5±1.9 *# 30.4±2.3 *# 27.8±1.6 *# |
Annotate: compare with matched group:
*P＜0.001; Compare with Composite Salvia Dropping Pill group: #P＜0.05;
Experimental result shows that compound red sage and chuanxiong rhizome oral preparation of the present invention has better pharmacological action than composite salvia dropping pill.
2. to the anoxybiotic protective effect experiment of mouse cardiac muscle
Experimental technique: get 80 of healthy Kunming mouses, body weight 18～22g is divided into 8 groups at random, matched group, composite salvia dropping pill group, compound red sage and chuanxiong rhizome oral preparation group of the present invention.Every group of male and female half and half, sub-cage rearing.With the conversion of people's conventional therapy dosage is the dosage of mice.The conversion formula is: tested animal is tried out the body surface area ratio of the body surface area ratio/known animal of dosage=known animals administer amount * tested animal.Control group administered physiological saline.Medication: 1 time/d, continuous 6d.1h is with urethane 1.2g/kg intraperitoneal injection of anesthesia after the last administration, and back fixation is separated trachea, with the bulldog clamp folder pipe of holding one's breath, observes electrocardio with electrocardiogram equipment, and writes down the little mousetrap with stopwatch and hold one's breath time of Guan Houzhi electrocardio disappearance, the results are shown in Table 3.
The anoxybiotic influence of table 3 pair mouse cardiac muscle
| Group | Mus number (only) | Mean survival time (min) |
| Matched group | 10 | 6.03±0.25 |
| Composite salvia dropping pill group | 10 | 10.39±0.29 * |
| Compound red sage and chuanxiong rhizome tablet compound red sage and chuanxiong rhizome granule compound red sage and chuanxiong rhizome capsule preparations compound red sage and chuanxiong rhizome soft capsule preparation compound red sage and chuanxiong rhizome dropping pill formulation compound red sage and chuanxiong rhizome oral liquid formulation | 10 10 10 10 10 10 | 13.67±0.35 *# 14.12±0.37 *# 15.08±0.34 *# 15.94±0.27 *# 16.58±0.54 *# 14.96±0.30 *# |
Annotate: compare with matched group:
*P＜0.001; Compare with Composite Salvia Dropping Pill group: #P＜0.05;
Experimental result shows that compound red sage and chuanxiong rhizome oral preparation of the present invention has better pharmacological action than composite salvia dropping pill.
3. to the protective effect of Beagle Cor Canitis myocardial ischemia
Get 8 of Beagle Canis familiaris L.s, body weight 7.5-10kg is divided into normal saline group, composite salvia dropping pill group, compound red sage and chuanxiong rhizome oral preparation group of the present invention.The administration group is respectively in the subcutaneous cephalic vein administration of Canis familiaris L. forelimb, the each 0.3g crude drug/kg of dosage, normal saline groups etc. are held inequality, administration every day 1 time, successive administration 3 days, pentobarbital sodium 25mg/kg intravenous anesthesia is used in administration after the 3rd day, tracheal intubation connects artificial respirator positive pressure respiration in addition, and the 5th rib is opened breast from the left side, cut off pericardium, expose heart, the pericardial incision edge is sewn in thoracic wall, divide the second stage of ligation at ramus descendens anterior arteriae coronariae sinistrae, and slow iv lignocaine 8mg/kg is in case the ventricular fibrillation that may cause before the ligation is sewed up pericardium and thoracic wall subsequently.24h behind the heart infarction, Canis familiaris L. is put to death after pentobarbital sodium anesthesia, take out heart rapidly, excision trunk and fatty tissue, check the position of anterior descending branch ligation point, claim heavy whole-heartedly, excise right ventricle and left atrium then, stay interventricular septum and left atrium, claim to such an extent that left ventricle is heavy, from the apex of the heart and beginning and anterior descending branch vertical direction left ventricle is cut into the thick flesh sheet of 2-3mm, be dipped in dyeing 30min in the nitro tetrazolium blue solution (NBT), cut ischemic region cardiac muscular tissue and weigh, the calculating myocardium infarction size, that is: heart infarction scope=ischemic region weight/left ventricle is heavy by * 100%, the results are shown in Table 4.
The influence of table 4 pair Cor Canitis chamber infarction size
| Group | Heavy (g) whole-heartedly | Chamber, a left side heavy (g) | Ischemic region heavy (g) | Heart infarction scope (%) |
| The normal saline group | 56.8±5.4 | 40.5±4.2 | 8.6±0.9 | 21.9±1.5 |
| Composite salvia dropping pill group | 59.9±3.8 | 42.3±4.6 | 4.5±0.6 | 10.2±0.5 * |
| Compound red sage and chuanxiong rhizome tablet compound red sage and chuanxiong rhizome granule compound red sage and chuanxiong rhizome capsule preparations compound red sage and chuanxiong rhizome soft capsule preparation compound red sage and chuanxiong rhizome dropping pill formulation compound red sage and chuanxiong rhizome oral liquid formulation | 59.0±5.2 58.6±4.6 58.1±5.3 57.5±3.9 57.0±5.1 58.2±4.7 | 42.0±4.6 41.9±3.5 41.2±4.2 41.0±4.3 40.9±5.1 41.8±4.2 | 3.2±0.4 3.0±0.3 2.8±0.5 2.5±0.4 2.1±0.2 2.6±0.5 | 8.3±0.2 ** 7.9±0.3 ** 6.8±0.4 ** 6.0±0.7 ** 5.2±0.5 ** 5.9±0.6 ** |
Annotate: compare with the normal saline group,
*P＜0.05,
*P＜0.01
Experimental result shows that compound red sage and chuanxiong rhizome oral preparation of the present invention has better pharmacological action than composite salvia dropping pill.
4. to the influence of isolated rat heart coronary flow
The female rat of body weight 250g-300g is divided into 8 groups at random, 6 every group.Get rat heart, with the oxygen enrichment (95%O of 7.4,36 ℃ of pH value
2And 5%CO
2) the krebs-henseteit nutritional solution, under constant temperature, constant-pressure conditions, do the isolated heart perfusion by the leagendonff method.After perfusion 1h treats the coronary flow substantially constant, measure 3 times (ml/min) with a small amount of tube continuously, get its meansigma methods and be the preceding flow of experiment, then by the side pipe dosing, normal saline group, composite salvia dropping pill group, compound red sage and chuanxiong rhizome oral preparation group of the present invention, dosage 0.8g crude drug/kg, the coronary flow result of variations sees 5 after the observed and recorded medication.
The influence of table 5 pair isolated rat heart coronary flow
| Group | Before the medicine | Behind the medicine | The P value |
| The normal saline group | 8.6±0.4 | 8.7±0.3 | ＞0.05 |
| Composite salvia dropping pill group | 7.3±0.3 | 7.7±0.5 | ＜0.05 |
| Compound red sage and chuanxiong rhizome tablet compound red sage and chuanxiong rhizome granule compound red sage and chuanxiong rhizome capsule preparations compound red sage and chuanxiong rhizome soft capsule preparation compound red sage and chuanxiong rhizome dropping pill formulation compound red sage and chuanxiong rhizome oral liquid formulation | 7.1±0.3 7.1±0.5 7.2±0.3 7.0±0.6 7.1±0.7 7.2±0.2 | 8.2±0.4 * 8.0±0.1 * 7.9±0.2 * 7.7±0.3 * 7.5±0.2 * 8.0±0.4 * | ＜0.01 ＜0.01 ＜0.01 ＜0.01 ＜0.01 ＜0.01 |
Annotate: the P value is for comparing before and after the administration in the table; Compare with positive controls
*P＜0.05
Experimental result shows that compound red sage and chuanxiong rhizome oral preparation of the present invention has better pharmacological action than composite salvia dropping pill.
5. acute toxicity testing
Get 140 of healthy mices, body weight 18-22g,, male and female half and half.Be divided into composite salvia dropping pill group, compound red sage and chuanxiong rhizome oral preparation group of the present invention, gastric infusion, dosage is according to 50 times of people's dosage, be converted into the mice dosage according to body surface area, administration every day 1 time continuous 7 days, is observed the dead mouse situation, record data, experimental result sees Table 6.
Table 6 chmice acute toxicity test
| Group | Number of animals (only) | Death toll (only) | Mortality rate (%) |
| Composite salvia dropping pill group | 20 | 4 | 20 |
| Compound red sage and chuanxiong rhizome tablet compound red sage and chuanxiong rhizome granule compound red sage and chuanxiong rhizome capsule preparations compound red sage and chuanxiong rhizome soft capsule preparation compound red sage and chuanxiong rhizome dropping pill formulation compound red sage and chuanxiong rhizome oral liquid formulation | 20 20 20 20 20 20 | 3 3 4 4 4 3 | 15 15 20 20 20 15 |
Above-mentioned experimental result shows: compound red sage and chuanxiong rhizome oral preparation of the present invention has good safety.
Four, preparation embodiment
Embodiment 1
1. the extraction of effective ingredient:
(1) gets Radix Salviae Miltiorrhizae 450g, Radix Notoginseng 150g and pulverize, use distilled water reflux, extract, 2 times, each 1h, filter, merge the water extract, being evaporated to relative density is 1.0, leave standstill centrifugalize, macroporous adsorptive resins on the supernatant, earlier be eluted to sugar-free with distilled water, continue with 40% ethanol elution, reclaim ethanol elution, concentrating under reduced pressure, drying gets Radix Salviae Miltiorrhizae, Radix Notoginseng total extract.
(2) get Rhizoma Chuanxiong medical material 150g and pulverize, the HCl ethanol with 0.5% (concentration of alcohol is 45%) reflux, extract,, the leaching medicinal liquid is concentrated into about 1g medical material/mL, uses Na
2CO
3Adjust pH to 7, with water saturated ethyl acetate extraction, extract reclaims ethyl acetate again with the saturated water washing of ethyl acetate, insoluble matter is with the hot water dissolving, last macroporous adsorptive resins, first water is eluted to colourless, the ethanol elution of reuse 60%, merge ethanol elution, concentrating under reduced pressure (＜60 ℃), drying obtains Rhizoma Chuanxiong extract.
(3) Borneolum Syntheticum becomes near saturated solution standby with anhydrous alcohol solution; Other gets the β-CD adding distil water of 3 times of amounts and makes saturated solution, and Borneolum Syntheticum ethanol liquid slowly is added drop-wise in β-CD saturated solution, does not stop to stir.After adding, 50 ℃ are continued to stir 2h again, and cold preservation is spent the night, and filters, and the precipitation cold drying gets the Borneolum Syntheticum beta-CD inclusion.
2. preparation prescription:
Tablet formulation consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 40g, and Rhizoma Chuanxiong extract 10g, Borneolum Syntheticum beta-CD inclusion 0.1g, pharmaceutic adjuvant are 30g;
The granule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 40g, Rhizoma Chuanxiong extract 10g, Borneolum Syntheticum beta-CD inclusion 0.1g, pharmaceutic adjuvant 100g;
The capsule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 40g, and Rhizoma Chuanxiong extract 10g, Borneolum Syntheticum beta-CD inclusion 0.1g, pharmaceutic adjuvant are 45g;
The soft capsule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 40g, and Rhizoma Chuanxiong extract 10g, Borneolum Syntheticum beta-CD inclusion 0.1g, pharmaceutic adjuvant are 150g;
The drop pill prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 40g, and Rhizoma Chuanxiong extract 10g, Borneolum Syntheticum beta-CD inclusion 0.1g, pharmaceutic adjuvant are 120g;
The oral liquid formulations prescription is formed: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 40g, and Rhizoma Chuanxiong extract 10g, Borneolum Syntheticum beta-CD inclusion 0.1g, pharmaceutic adjuvant are 5g;
3. formulation preparation:
Form according to preparation prescription, be prepared into 1000 in tablet, 1000 bags of granules, 1000 of capsules, 1000 of soft capsules, 1000 bags of drop pills, 1000 bags of oral liquid formulations with conventional pharmaceutical technology;
Embodiment 2
1. the extraction of effective ingredient:
(1) gets Radix Salviae Miltiorrhizae 1500g, Radix Notoginseng 500g and pulverize, use distilled water reflux, extract, 2 times, each 3h, filter, merge the water extract, being evaporated to relative density is 1.1, leave standstill centrifugalize, macroporous adsorptive resins on the supernatant, earlier be eluted to sugar-free with distilled water, continue with 45% ethanol elution, reclaim ethanol elution, concentrating under reduced pressure, drying gets Radix Salviae Miltiorrhizae, Radix Notoginseng total extract.
(2) get Rhizoma Chuanxiong medical material 500g and pulverize, the HCl ethanol with 1% (concentration of alcohol is 50%) reflux, extract,, the leaching medicinal liquid is concentrated into about 2g medical material/mL, uses Na
2CO
3Adjust pH to 7.5, with water saturated ethyl acetate extraction, extract reclaims ethyl acetate again with the saturated water washing of ethyl acetate, insoluble matter is with the hot water dissolving, last macroporous adsorptive resins, first water is eluted to colourless, the ethanol elution of reuse 65%, merge ethanol elution, concentrating under reduced pressure (＜60 ℃), drying obtains Rhizoma Chuanxiong extract.
(3) Borneolum Syntheticum becomes near saturated solution standby with anhydrous alcohol solution; Other gets the β-CD adding distil water of 5 times of amounts and makes saturated solution, and Borneolum Syntheticum ethanol liquid slowly is added drop-wise in β-CD saturated solution, does not stop to stir.After adding, 55 ℃ are continued to stir 3h again, and cold preservation is spent the night, and filters, and the precipitation cold drying gets the Borneolum Syntheticum beta-CD inclusion.
2. preparation prescription:
Tablet formulation consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 50g, and Rhizoma Chuanxiong extract 12g, Borneolum Syntheticum beta-CD inclusion 0.2g, pharmaceutic adjuvant are 180g;
The granule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 50g, Rhizoma Chuanxiong extract 12g, Borneolum Syntheticum beta-CD inclusion 0.2g, pharmaceutic adjuvant 300g;
The capsule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 50g, and Rhizoma Chuanxiong extract 12g, Borneolum Syntheticum beta-CD inclusion 0.2g, pharmaceutic adjuvant are 85g;
The soft capsule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 50g, and Rhizoma Chuanxiong extract 12g, Borneolum Syntheticum beta-CD inclusion 0.2g, pharmaceutic adjuvant are 160g;
The drop pill prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 50g, and Rhizoma Chuanxiong extract 12g, Borneolum Syntheticum beta-CD inclusion 0.2g, pharmaceutic adjuvant are 150g;
The oral liquid formulations prescription is formed: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 50g, and Rhizoma Chuanxiong extract 12g, Borneolum Syntheticum beta-CD inclusion 0.2g, pharmaceutic adjuvant are 8g;
3. formulation preparation:
Form according to preparation prescription, be prepared into 1000 in tablet, 1000 bags of granules, 1000 of capsules, 1000 of soft capsules, 1000 bags of drop pills, 1000 bags of oral liquid formulations with conventional pharmaceutical technology;
Embodiment 3
1. the extraction of effective ingredient:
(1) gets Radix Salviae Miltiorrhizae 3000g, Radix Notoginseng 1000g and pulverize, use distilled water reflux, extract, 4 times, each 1.5h, filter, merge the water extract, being evaporated to relative density is 1.5, leave standstill centrifugalize, macroporous adsorptive resins on the supernatant, earlier be eluted to sugar-free with distilled water, continue with 50% ethanol elution, reclaim ethanol elution, concentrating under reduced pressure, drying gets Radix Salviae Miltiorrhizae, Radix Notoginseng total extract.
(2) get Rhizoma Chuanxiong medical material 1000g and pulverize, the HCl ethanol with 1.2% (concentration of alcohol is 55%) reflux, extract,, the leaching medicinal liquid is concentrated into about 1.3g medical material/mL, uses Na
2CO
3Adjust pH to 8, with water saturated ethyl acetate extraction, extract reclaims ethyl acetate again with the saturated water washing of ethyl acetate, insoluble matter is with the hot water dissolving, last macroporous adsorptive resins, first water is eluted to colourless, the ethanol elution of reuse 70%, merge ethanol elution, concentrating under reduced pressure (＜60 ℃), drying obtains Rhizoma Chuanxiong extract.
(3) Borneolum Syntheticum becomes near saturated solution standby with the molten alcoholysis of anhydrous second; Other gets the β-CD adding distil water of 6 times of amounts and makes saturated solution, and Borneolum Syntheticum ethanol liquid slowly is added drop-wise in β-CD saturated solution, does not stop to stir.After adding, 45 ℃ are continued to stir 3h again, and cold preservation is spent the night, and filters, and the precipitation cold drying gets the Borneolum Syntheticum beta-CD inclusion.
2. preparation prescription:
Tablet formulation consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 80g, and Rhizoma Chuanxiong extract 24g, Borneolum Syntheticum beta-CD inclusion 0.4g, pharmaceutic adjuvant are 250g;
The granule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 80g, Rhizoma Chuanxiong extract 24g, Borneolum Syntheticum beta-CD inclusion 0.4g, pharmaceutic adjuvant 500g;
The capsule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 80g, and Rhizoma Chuanxiong extract 24g, Borneolum Syntheticum beta-CD inclusion 0.4g, pharmaceutic adjuvant are 280g;
The soft capsule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 80g, and Rhizoma Chuanxiong extract 24g, Borneolum Syntheticum beta-CD inclusion 0.4g, pharmaceutic adjuvant are 260g;
The drop pill prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 80g, and Rhizoma Chuanxiong extract 24g, Borneolum Syntheticum beta-CD inclusion 0.4g, pharmaceutic adjuvant are 300g;
The oral liquid formulations prescription is formed: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 80g, and Rhizoma Chuanxiong extract 24g, Borneolum Syntheticum beta-CD inclusion 0.4g, pharmaceutic adjuvant are 12g;
3. formulation preparation:
Form according to preparation prescription, be prepared into 1000 in tablet, 1000 bags of granules, 1000 of capsules, 1000 of soft capsules, 1000 bags of drop pills, 1000 bags of oral liquid formulations with conventional pharmaceutical technology;
Embodiment 4
1. the extraction of effective ingredient:
(1) gets Radix Salviae Miltiorrhizae 4500g, Radix Notoginseng 1500g and pulverize, use distilled water reflux, extract, 2 times, each 1h, filter, merge the water extract, being evaporated to relative density is 1.4, leave standstill centrifugalize, macroporous adsorptive resins on the supernatant, earlier be eluted to sugar-free with distilled water, continue with 60% ethanol elution, reclaim ethanol elution, concentrating under reduced pressure, drying gets Radix Salviae Miltiorrhizae, Radix Notoginseng total extract.
(2) get Rhizoma Chuanxiong medical material 1500g and pulverize, the HCl ethanol with 1.5% (concentration of alcohol is 60%) reflux, extract,, the leaching medicinal liquid is concentrated into about 1.2g medical material/mL, uses Na
2CO
3Adjust pH to 8.5, with water saturated ethyl acetate extraction, extract reclaims ethyl acetate again with the saturated water washing of ethyl acetate, insoluble matter is with the hot water dissolving, last macroporous adsorptive resins, first water is eluted to colourless, the ethanol elution of reuse 60%, merge ethanol elution, concentrating under reduced pressure (＜60 ℃), drying obtains Rhizoma Chuanxiong extract.
(3) Borneolum Syntheticum becomes near saturated solution standby with anhydrous alcohol solution; Other gets the β-CD adding distil water of 8 times of amounts and makes saturated solution, and Borneolum Syntheticum ethanol liquid slowly is added drop-wise in β-CD saturated solution, does not stop to stir.After adding, 50 ℃ are continued to stir 2h again, and cold preservation is spent the night, and filters, and the precipitation cold drying gets the Borneolum Syntheticum beta-CD inclusion.
2. preparation prescription:
Tablet formulation consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 100g, and Rhizoma Chuanxiong extract 25g, Borneolum Syntheticum beta-CD inclusion 0.5g, pharmaceutic adjuvant are 360g;
The granule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 100g, Rhizoma Chuanxiong extract 25g, Borneolum Syntheticum beta-CD inclusion 0.5g, pharmaceutic adjuvant 1000g;
The capsule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 100g, and Rhizoma Chuanxiong extract 25g, Borneolum Syntheticum beta-CD inclusion 0.5g, pharmaceutic adjuvant are 370g;
The soft capsule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 100g, and Rhizoma Chuanxiong extract 25g, Borneolum Syntheticum beta-CD inclusion 0.5g, pharmaceutic adjuvant are 500g;
The drop pill prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 100g, and Rhizoma Chuanxiong extract 25g, Borneolum Syntheticum beta-CD inclusion 0.5g, pharmaceutic adjuvant are 750g;
The oral liquid formulations prescription is formed: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 100g, and Rhizoma Chuanxiong extract 25g, Borneolum Syntheticum beta-CD inclusion 0.5g, pharmaceutic adjuvant are 15g;
3. formulation preparation:
Form according to preparation prescription, be prepared into 1000 in tablet, 1000 bags of granules, 1000 of capsules, 1000 of soft capsules, 1000 bags of drop pills, 1000 bags of oral liquid formulations with conventional pharmaceutical technology;
Embodiment 5
1. the extraction of effective ingredient:
(1) gets Radix Salviae Miltiorrhizae 1200g, Radix Notoginseng 500g and pulverize, use distilled water reflux, extract, 4 times, each 3h, filter, merge the water extract, being evaporated to relative density is 1.3, leave standstill centrifugalize, macroporous adsorptive resins on the supernatant, earlier be eluted to sugar-free with distilled water, continue with 65% ethanol elution, reclaim ethanol elution, concentrating under reduced pressure, drying gets Radix Salviae Miltiorrhizae, Radix Notoginseng total extract.
(2) get Rhizoma Chuanxiong medical material 500g and pulverize, the HCl ethanol with 2% (concentration of alcohol is 65%) reflux, extract,, the leaching medicinal liquid is concentrated into about 2g medical material/mL, uses Na
2CO
3Adjust pH to 9, with water saturated ethyl acetate extraction, extract reclaims ethyl acetate again with the saturated water washing of ethyl acetate, insoluble matter is with the hot water dissolving, last macroporous adsorptive resins, first water is eluted to colourless, the ethanol elution of reuse 55%, merge ethanol elution, concentrating under reduced pressure (＜60 ℃), drying obtains Rhizoma Chuanxiong extract.
(3) Borneolum Syntheticum becomes near saturated solution standby with anhydrous alcohol solution; Other gets the β-CD adding distil water of 10 times of amounts and makes saturated solution, and Borneolum Syntheticum ethanol liquid slowly is added drop-wise in β-CD saturated solution, does not stop to stir.After adding, 55 ℃ are continued to stir 4h again, and cold preservation is spent the night, and filters, and the precipitation cold drying gets the Borneolum Syntheticum beta-CD inclusion.
2. preparation prescription:
Tablet formulation consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 60g, and Rhizoma Chuanxiong extract 15g, Borneolum Syntheticum beta-CD inclusion 0.2g, pharmaceutic adjuvant are 150g;
The granule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 60g, Rhizoma Chuanxiong extract 15g, Borneolum Syntheticum beta-CD inclusion 0.2g, pharmaceutic adjuvant 300g;
The capsule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 60g, and Rhizoma Chuanxiong extract 15g, Borneolum Syntheticum beta-CD inclusion 0.2g, pharmaceutic adjuvant are 180g;
The soft capsule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 60g, and Rhizoma Chuanxiong extract 15g, Borneolum Syntheticum beta-CD inclusion 0.2g, pharmaceutic adjuvant are 280g;
The drop pill prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 60g, and Rhizoma Chuanxiong extract 15g, Borneolum Syntheticum beta-CD inclusion 0.2g, pharmaceutic adjuvant are 180g;
The oral liquid formulations prescription is formed: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 60g, and Rhizoma Chuanxiong extract 15g, Borneolum Syntheticum beta-CD inclusion 0.2g, pharmaceutic adjuvant are 10g;
3. formulation preparation:
Form according to preparation prescription, be prepared into 1000 in tablet, 1000 bags of granules, 1000 of capsules, 1000 of soft capsules, 1000 bags of drop pills, 1000 bags of oral liquid formulations with conventional pharmaceutical technology;
Embodiment 6
1. the extraction of effective ingredient:
(1) gets Radix Salviae Miltiorrhizae 1500g, Radix Notoginseng 600g and pulverize, use distilled water reflux, extract, 2 times, each 2.5h, filter, merge the water extract, being evaporated to relative density is 1.2, leave standstill centrifugalize, macroporous adsorptive resins on the supernatant, earlier be eluted to sugar-free with distilled water, continue with 80% ethanol elution, reclaim ethanol elution, concentrating under reduced pressure, drying gets Radix Salviae Miltiorrhizae, Radix Notoginseng total extract.
(2) get Rhizoma Chuanxiong medical material 500g and pulverize, the HCl ethanol with 3% (concentration of alcohol is 75%) reflux, extract,, the leaching medicinal liquid is concentrated into about 2g medical material/mL, uses Na
2CO
3Adjust pH to 10, with water saturated ethyl acetate extraction, extract reclaims ethyl acetate again with the saturated water washing of ethyl acetate, insoluble matter is with the hot water dissolving, last macroporous adsorptive resins, first water is eluted to colourless, the ethanol elution of reuse 50%, merge ethanol elution, concentrating under reduced pressure (＜60 ℃), drying obtains Rhizoma Chuanxiong extract.
(3) Borneolum Syntheticum becomes near saturated solution standby with anhydrous alcohol solution; Other gets the β-CD adding distil water of 15 times of amounts and makes saturated solution, and Borneolum Syntheticum ethanol liquid slowly is added drop-wise in β-CD saturated solution, does not stop to stir.After adding, 45 ℃ are continued to stir 3h again, and cold preservation is spent the night, and filters, and the precipitation cold drying gets the Borneolum Syntheticum beta-CD inclusion.
2. preparation prescription:
Tablet formulation consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 75g, and Rhizoma Chuanxiong extract 20g, Borneolum Syntheticum beta-CD inclusion 0.3g, pharmaceutic adjuvant are 300g;
The granule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 75g, Rhizoma Chuanxiong extract 20g, Borneolum Syntheticum beta-CD inclusion 0.3g, pharmaceutic adjuvant 650g;
The capsule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 75g, and Rhizoma Chuanxiong extract 20g, Borneolum Syntheticum beta-CD inclusion 0.3g, pharmaceutic adjuvant are 180g;
The soft capsule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 75g, and Rhizoma Chuanxiong extract 20g, Borneolum Syntheticum beta-CD inclusion 0.3g, pharmaceutic adjuvant are 250g;
The drop pill prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 75g, and Rhizoma Chuanxiong extract 20g, Borneolum Syntheticum beta-CD inclusion 0.3g, pharmaceutic adjuvant are 240g;
The oral liquid formulations prescription is formed: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 75g, and Rhizoma Chuanxiong extract 20g, Borneolum Syntheticum beta-CD inclusion 0.3g, pharmaceutic adjuvant are 15g;
3. formulation preparation:
Form according to preparation prescription, be prepared into 1000 in tablet, 1000 bags of granules, 1000 of capsules, 1000 of soft capsules, 1000 bags of drop pills, 1000 bags of oral liquid formulations with conventional pharmaceutical technology;
Embodiment 7
1. the extraction of effective ingredient:
(1) gets Radix Salviae Miltiorrhizae 700g, Radix Notoginseng 200g pulverizing medicinal materials, use distilled water reflux, extract, 4 times, each 2h, filter, merge the water extract, being evaporated to relative density is 1.1, leave standstill centrifugalize, macroporous adsorptive resins on the supernatant, earlier be eluted to sugar-free with distilled water, continue with 75% ethanol elution, reclaim ethanol elution, concentrating under reduced pressure, drying gets Radix Salviae Miltiorrhizae, Radix Notoginseng total extract.
(2) get Rhizoma Chuanxiong medical material 200g and pulverize, the HCl ethanol with 2.5% (concentration of alcohol is 70%) reflux, extract,, the leaching medicinal liquid is concentrated into about 1.6g medical material/mL, uses Na
2CO
3Adjust pH to 9.5, with water saturated ethyl acetate extraction, extract reclaims ethyl acetate again with the saturated water washing of ethyl acetate, insoluble matter is with the hot water dissolving, last macroporous adsorptive resins, first water is eluted to colourless, the ethanol elution of reuse 45%, merge ethanol elution, concentrating under reduced pressure (＜60 ℃), drying obtains Rhizoma Chuanxiong extract.
(3) Borneolum Syntheticum becomes near saturated solution standby with anhydrous alcohol solution; Other gets the β-CD adding distil water of 12 times of amounts and makes saturated solution, and Borneolum Syntheticum ethanol liquid slowly is added drop-wise in β-CD saturated solution, does not stop to stir.After adding, 50 ℃ are continued to stir 3h again, and cold preservation is spent the night, and filters, and the precipitation cold drying gets the Borneolum Syntheticum beta-CD inclusion.
2. preparation prescription:
Tablet formulation consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 12g, and Rhizoma Chuanxiong extract 4g, Borneolum Syntheticum beta-CD inclusion 0.04g, pharmaceutic adjuvant are 16g;
The granule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 12g, Rhizoma Chuanxiong extract 4g, Borneolum Syntheticum beta-CD inclusion 0.04g, pharmaceutic adjuvant 50g;
The capsule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 12g, and Rhizoma Chuanxiong extract 4g, Borneolum Syntheticum beta-CD inclusion 0.04g, pharmaceutic adjuvant are 35g;
The soft capsule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 12g, and Rhizoma Chuanxiong extract 4g, Borneolum Syntheticum beta-CD inclusion 0.04g, pharmaceutic adjuvant are 55g;
The drop pill prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 12g, and Rhizoma Chuanxiong extract 4g, Borneolum Syntheticum beta-CD inclusion 0.04g, pharmaceutic adjuvant are 48g;
The oral liquid formulations prescription is formed: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 12g, and Rhizoma Chuanxiong extract 4g, Borneolum Syntheticum beta-CD inclusion 0.04g, pharmaceutic adjuvant are 3g;
3. formulation preparation:
Form according to preparation prescription, be prepared into 1000 in tablet, 1000 bags of granules, 1000 of capsules, 1000 of soft capsules, 1000 bags of drop pills, 1000 bags of oral liquid formulations with conventional pharmaceutical technology;
Embodiment 8
1. the extraction of effective ingredient:
(1) gets Radix Salviae Miltiorrhizae 450g, Radix Notoginseng 150g and pulverize, use distilled water reflux, extract, 2 times, each 1h, filter, merge the water extract, being evaporated to relative density is 1.0, leave standstill centrifugalize, macroporous adsorptive resins on the supernatant, earlier be eluted to sugar-free with distilled water, continue with 70% ethanol elution, reclaim ethanol elution, concentrating under reduced pressure, drying gets Radix Salviae Miltiorrhizae, Radix Notoginseng total extract.
(2) get Rhizoma Chuanxiong medical material 150g and pulverize, the HCl ethanol with 2.5% (concentration of alcohol is 70%) reflux, extract,, the leaching medicinal liquid is concentrated into about 2g medical material/mL, uses Na
2CO
3Adjust pH to 9, with water saturated ethyl acetate extraction, extract reclaims ethyl acetate again with the saturated water washing of ethyl acetate, insoluble matter is with the hot water dissolving, last macroporous adsorptive resins, first water is eluted to colourless, the ethanol elution of reuse 40%, merge ethanol elution, concentrating under reduced pressure (＜60 ℃), drying obtains Rhizoma Chuanxiong extract.
(3) Borneolum Syntheticum becomes near saturated solution standby with anhydrous alcohol solution; Other gets the β-CD adding distil water of 10 times of amounts and makes saturated solution, and Borneolum Syntheticum ethanol liquid slowly is added drop-wise in β-CD saturated solution, does not stop to stir.After adding, 50 ℃ are continued to stir 4h again, and cold preservation is spent the night, and filters, and the precipitation cold drying gets the Borneolum Syntheticum beta-CD inclusion.
2. preparation prescription:
Tablet formulation consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 6g, and Rhizoma Chuanxiong extract 2g, Borneolum Syntheticum beta-CD inclusion 0.01g, pharmaceutic adjuvant are 4g;
The granule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 6g, Rhizoma Chuanxiong extract 2g, Borneolum Syntheticum beta-CD inclusion 0.01g, pharmaceutic adjuvant 16g;
The capsule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 6g, and Rhizoma Chuanxiong extract 2g, Borneolum Syntheticum beta-CD inclusion 0.01g, pharmaceutic adjuvant are 4g;
The soft capsule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 6g, and Rhizoma Chuanxiong extract 2g, Borneolum Syntheticum beta-CD inclusion 0.01g, pharmaceutic adjuvant are 8g;
The drop pill prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 6g, and Rhizoma Chuanxiong extract 2g, Borneolum Syntheticum beta-CD inclusion 0.01g, pharmaceutic adjuvant are 16g;
The oral liquid formulations prescription is formed: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 6g, and Rhizoma Chuanxiong extract 2g, Borneolum Syntheticum beta-CD inclusion 0.01g, pharmaceutic adjuvant are 6g;
3. formulation preparation:
Form according to preparation prescription, be prepared into 1000 in tablet, 1000 bags of granules, 1000 of capsules, 1000 of soft capsules, 1000 bags of drop pills, 1000 bags of oral liquid formulations with conventional pharmaceutical technology.
Claims (3)
1. compound red sage and chuanxiong rhizome oral preparation is characterized in that its crude drug prescription is:
Radix Salviae Miltiorrhizae 150-300 weight portion, Radix Notoginseng 50-100 weight portion, Rhizoma Chuanxiong 50-100 weight portion, Borneolum Syntheticum 0.5-3 weight portion.
2. the preparation method of a compound red sage and chuanxiong rhizome oral preparation, its feature may further comprise the steps:
(1) extraction of effective ingredient:
A. get Radix Salviae Miltiorrhizae, pseudo-ginseng pulverizing, use distilled water reflux, extract, 2-4 time, each 1-3 hour, filter, merge the water extract, being evaporated to relative density is 1.0～1.5, leave standstill centrifugalize, macroporous adsorptive resins on the supernatant, earlier be eluted to sugar-free, continue, reclaim ethanol elution with the ethanol elution of 40-80% with distilled water, concentrating under reduced pressure, drying gets Radix Salviae Miltiorrhizae, Radix Notoginseng total extract, and being mainly with the danshensu is the Radix Salviae Miltiorrhizae acids and the Radix Notoginseng total arasaponins of main component;
B. get the Rhizoma Chuanxiong pulverizing medicinal materials, with the HCl ethanol of 0.5-3%, the concentration of alcohol is the 45-75% reflux, extract,, and the leaching medicinal liquid is concentrated into about 1-2g medical material/mL, uses Na
2CO
3Adjust pH to 7～10, with water saturated ethyl acetate extraction, extract reclaims ethyl acetate again with the saturated water washing of ethyl acetate, insoluble matter is with the hot water dissolving, last macroporous adsorptive resins, first water is eluted to colourless, the ethanol elution of reuse 40-70%, merge ethanol elution, temperature is lower than concentrating under reduced pressure under 60 ℃ of conditions, drying, and obtaining with the ligustrazine is the Rhizoma Chuanxiong extract of main active;
C. Borneolum Syntheticum becomes near saturated solution standby with anhydrous alcohol solution; Other gets β-CD adding distil water that 3-15 doubly measures and makes saturated solution, and Borneolum Syntheticum ethanol liquid slowly is added drop-wise in β-CD saturated solution, does not stop to stir.After adding, 50+5 ℃ is continued to stir 2-4 hour again, and cold preservation is spent the night, and filters, and the precipitation cold drying gets the Borneolum Syntheticum beta-CD inclusion;
(2) preparation prescription:
Tablet formulation consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 4-10 weight portion, and Rhizoma Chuanxiong extract 1-3 weight portion, Borneolum Syntheticum beta-CD inclusion 0.01-0.6 weight portion, pharmaceutic adjuvant is the 2.5-40 weight portion;
The granule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 4-10 weight portion, Rhizoma Chuanxiong extract 1-3 weight portion, Borneolum Syntheticum beta-CD inclusion 0.01-0.6 weight portion, pharmaceutic adjuvant 5-110 weight portion;
The capsule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 4-10 weight portion, and Rhizoma Chuanxiong extract 1-3 weight portion, Borneolum Syntheticum beta-CD inclusion 0.01-0.6 weight portion, pharmaceutic adjuvant is the 5-40 weight portion;
The soft capsule prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 4-10 weight portion, and Rhizoma Chuanxiong extract 1-3 weight portion, Borneolum Syntheticum beta-CD inclusion 0.01-0.6 weight portion, pharmaceutic adjuvant is the 5-55 weight portion;
The drop pill prescription consists of: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 4-10 weight portion, and Rhizoma Chuanxiong extract 1-3 weight portion, Borneolum Syntheticum beta-CD inclusion 0.01-0.6 weight portion, pharmaceutic adjuvant is the 10-82 weight portion;
The oral liquid formulations prescription is formed: Radix Salviae Miltiorrhizae, Radix Notoginseng total extract 4-10 weight portion, and Rhizoma Chuanxiong extract 1-3 weight portion, Borneolum Syntheticum beta-CD inclusion 0.01-0.6 weight portion, pharmaceutic adjuvant is the 0.5-2 weight portion;
(3) formulation preparation:
Get Radix Salviae Miltiorrhizae, Radix Notoginseng total extract, Rhizoma Chuanxiong extract and Borneolum Syntheticum beta-CD inclusion, add acceptable pharmaceutic adjuvant on the pharmaceutics, be prepared into tablet, granule, capsule, soft capsule, drop pill, oral liquid formulations with conventional pharmaceutical technology;
3. a kind of according to claim 1 compound red sage and chuanxiong rhizome oral preparation is characterized in that being mainly used in the disease of cardiovascular aspects such as treatment coronary heart disease, angina pectoris.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510132502 CN1985881A (en) | 2005-12-23 | 2005-12-23 | Preparing process and application of compound red sage and chuanxiong rhizome oral preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510132502 CN1985881A (en) | 2005-12-23 | 2005-12-23 | Preparing process and application of compound red sage and chuanxiong rhizome oral preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1985881A true CN1985881A (en) | 2007-06-27 |
Family
ID=38182908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510132502 Pending CN1985881A (en) | 2005-12-23 | 2005-12-23 | Preparing process and application of compound red sage and chuanxiong rhizome oral preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1985881A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102940680A (en) * | 2012-10-31 | 2013-02-27 | 成都医路康医学技术服务有限公司 | Medicine composition for treating cardia-cerebrovascular diseases |
| CN105148288A (en) * | 2015-09-30 | 2015-12-16 | 河南行知专利服务有限公司 | Cyclodextrin-and-modified-cyclodextrin-assisted method for extracting effective ingredients of traditional Chinese medicinal materials |
| CN113350264A (en) * | 2021-06-18 | 2021-09-07 | 周宇 | Compound red sage root oral preparation and its preparing process |
-
2005
- 2005-12-23 CN CN 200510132502 patent/CN1985881A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102940680A (en) * | 2012-10-31 | 2013-02-27 | 成都医路康医学技术服务有限公司 | Medicine composition for treating cardia-cerebrovascular diseases |
| CN102940680B (en) * | 2012-10-31 | 2014-11-26 | 成都医路康医学技术服务有限公司 | Medicine composition for treating cardia-cerebrovascular diseases |
| CN105148288A (en) * | 2015-09-30 | 2015-12-16 | 河南行知专利服务有限公司 | Cyclodextrin-and-modified-cyclodextrin-assisted method for extracting effective ingredients of traditional Chinese medicinal materials |
| CN113350264A (en) * | 2021-06-18 | 2021-09-07 | 周宇 | Compound red sage root oral preparation and its preparing process |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100450501C (en) | Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases and preparing process thereof | |
| CN100569219C (en) | A kind of pharmaceutical composition that is used for oral formulations and preparation method thereof | |
| CN101116722A (en) | Pharmaceutical formulations with the raw material containing panax, ophiopogon root and schisandra fruit, processes for their preparation, the raw material and the quality control method for the prepa | |
| CN1899400B (en) | Detection method for injection containing ginseng and aconite root in raw material | |
| CN1931236B (en) | Medicine composition of red sage and rhodiola root | |
| CN101537039A (en) | Moldavica dragonhead general flavone extract as well as preparation method and application thereof | |
| CN101085000B (en) | Compound red sage root freezing-dried powder injection containing salvianolic acid B and its preparation method | |
| CN103837609A (en) | Pulse-activating injection and preparation method thereof | |
| CN100536900C (en) | Traditional Chinese medicinal composition for treating coronary disease and its preparation method | |
| CN1985881A (en) | Preparing process and application of compound red sage and chuanxiong rhizome oral preparation | |
| CN100467025C (en) | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| CN101085001B (en) | Compound red sage root freezing-dried powder injection containing tanshinol and its preparation method | |
| CN1931233B (en) | Medicine composition of red sage and epimedium for treating cardiac and cerebral vascular diseases | |
| CN1923228B (en) | Pharmaceutical composition comprising notoginseng extract, Danshen extract and ligustrazine | |
| CN102475766B (en) | Drug composition for treating heart failure, preparation method and application of drug composition | |
| CN100563647C (en) | The Pharmaceutical composition of Herba Erigerontis and sodium tanshinon IIA silate injection | |
| CN1923229B (en) | Pharmaceutical composition comprising notoginseng extract, Danshen extract and puerarin | |
| CN1994277B (en) | Solid preparation of salvianolic acid A of red sage root and preparation process thereof | |
| CN101152285A (en) | Pharmaceutical composition of snakegourd fruit and whitethorn leaf | |
| CN101152246B (en) | Pharmaceutical composition for cardiovascular and cerebrovascular diseases and method for preparing the same | |
| CN101176769B (en) | Pharmaceutical composition of cattail pollen and red orpin | |
| CN100364566C (en) | Compound red sage root spray and its preparing method | |
| CN101696166B (en) | Preparation method for danshen root salvianolic acid A | |
| CN111544473A (en) | Refined coronary heart disease granule extraction preparation process for treating coronary heart disease and angina pectoris, traditional Chinese medicine and extract thereof | |
| CN101176751B (en) | Pharmaceutical composition of red sage root and cassia twig |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20070627 |